Novavax delays U.S. trial of COVID-19 vaccine candidate to November

(Reuters) – Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.

The U.S.-based drug developer said data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021 and could be the basis for regulatory approval, sending its shares up 3.4% in early trading.

 

Reuters source: